Ra Capital Management, L.P.

Director

Ra Capital Management, L.P. (Director) filed 31 Form 4 reports as a reporting entity in the trailing twelve months (23 purchases, 8 sales, 1 filed past the two-business-day deadline), most often in Artiva Biotherapeutics, Inc. (ARTV). Across 22 priced purchase filings, the average 21-session return was +16.2% from execution and +14.2% from disclosure (delay-adjusted; derived). The largest single filing was $423.8M of PBLS (21,188,750 sh across 2 lots, as filed), executed Jun 11. Data as of Nov 7 2026.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

+16.2%

avg across 22 priced filings

Delay-adjustediThe same average, entered at disclosure dates

+14.2%

same 22 filings, from disclosure

Filings, ttm

23 buys · 8 sells · 1 late

Median delay

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$871.5M

shares × price, as filed

Last traded

Nov 2

Filed Nov 3

Median ADV $10.0M across their filed names

Impact on $10,000 · 12M

$25,798 (+158.0%)

S&P 500 $10,907 (+9.1%) · 148.9 pts ahead

Ra Capital Management, L.P. S&P 500

Derived: compounded across filings from disclosure dates · past 12 months

Open performance→

Volume by month

Buys $856.6M Sells $128.1M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 25 filings Not on file 5 filings

Sector per market data · by filing · past 12 months

Most traded names

ARTV

Artiva Biotherapeutics, Inc. ARTV · 9 buys · 0 sells 9 filings COAG

Hemab Therapeutics Holdings, Inc. COAG · 4 buys · 0 sells 4 filings SION

Sionna Therapeutics, Inc. SION · 1 buy · 2 sells 3 filings VOR VOR 0 buys · 3 sells 3 filings HOWL

Werewolf Therapeutics, Inc. HOWL · 0 buys · 2 sells 2 filings

Recent filings

BBTXPURCHASE Bambusa Therapeutics, Inc. Common stock View filing → $46.6M
2,953,820 sh across 4 lots
Exec Oct 30
Filed Nov 3 · 6:09 PM ET LENZSALE LENZ Therapeutics, Inc. View filing → $9.1M
2,718,684 sh across 3 lots
Exec Oct 29
Filed Nov 2 · 5:44 PM ET SIONSALE Sionna Therapeutics, Inc. View filing → $21.8M
3,448,811 sh across 2 lots
Exec Sep 17
Filed Sep 21 · 6:56 PM ET SEPNSALE Septerna, Inc. View filing → $63.5M
1,493,000 sh across 2 lots
Exec Aug 12
Filed Aug 14 · 5:11 PM ET ARTVPURCHASE Artiva Biotherapeutics, Inc. View filing → $456K
45,768 sh across 2 lots
Exec Jul 29
Filed Jul 31 · 5:13 PM ET ARTVPURCHASE Artiva Biotherapeutics, Inc. View filing → $413K
41,319 sh × $9.99
Exec Jul 24
Filed Jul 28 · 5:24 PM ET ARTVPURCHASE Artiva Biotherapeutics, Inc. View filing → $2.6M
264,586 sh across 3 lots
Exec Jul 21
Filed Jul 23 · 9:22 PM ET PBLSPURCHASE Parabilis Medicines, Inc. View filing → $6.9M
244,593 sh across 6 lots
Exec Jul 20
Filed Jul 22 · 4:55 PM ET More filings →